Cargando…

Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications

SIMPLE SUMMARY: Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bella, Ángela, Di Trani, Claudia Augusta, Fernández-Sendin, Myriam, Arrizabalaga, Leire, Cirella, Assunta, Teijeira, Álvaro, Medina-Echeverz, José, Melero, Ignacio, Berraondo, Pedro, Aranda, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956655/
https://www.ncbi.nlm.nih.gov/pubmed/33669017
http://dx.doi.org/10.3390/cancers13050963
_version_ 1783664486084771840
author Bella, Ángela
Di Trani, Claudia Augusta
Fernández-Sendin, Myriam
Arrizabalaga, Leire
Cirella, Assunta
Teijeira, Álvaro
Medina-Echeverz, José
Melero, Ignacio
Berraondo, Pedro
Aranda, Fernando
author_facet Bella, Ángela
Di Trani, Claudia Augusta
Fernández-Sendin, Myriam
Arrizabalaga, Leire
Cirella, Assunta
Teijeira, Álvaro
Medina-Echeverz, José
Melero, Ignacio
Berraondo, Pedro
Aranda, Fernando
author_sort Bella, Ángela
collection PubMed
description SIMPLE SUMMARY: Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedical research. ABSTRACT: Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Syngeneic tumor cell lines, human xenografts, patient-derived xenografts, genetically induced tumors, and 3D scaffold biomimetics. Each experimental model has its own strengths and limitations, all of which can influence the subsequent translational results concerning anticancer and immunomodulatory drugs under exploration. This review highlights the current status of peritoneal carcinomatosis mouse models for preclinical development of anticancer drugs or immunotherapeutic agents.
format Online
Article
Text
id pubmed-7956655
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79566552021-03-16 Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications Bella, Ángela Di Trani, Claudia Augusta Fernández-Sendin, Myriam Arrizabalaga, Leire Cirella, Assunta Teijeira, Álvaro Medina-Echeverz, José Melero, Ignacio Berraondo, Pedro Aranda, Fernando Cancers (Basel) Review SIMPLE SUMMARY: Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedical research. ABSTRACT: Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Syngeneic tumor cell lines, human xenografts, patient-derived xenografts, genetically induced tumors, and 3D scaffold biomimetics. Each experimental model has its own strengths and limitations, all of which can influence the subsequent translational results concerning anticancer and immunomodulatory drugs under exploration. This review highlights the current status of peritoneal carcinomatosis mouse models for preclinical development of anticancer drugs or immunotherapeutic agents. MDPI 2021-02-25 /pmc/articles/PMC7956655/ /pubmed/33669017 http://dx.doi.org/10.3390/cancers13050963 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bella, Ángela
Di Trani, Claudia Augusta
Fernández-Sendin, Myriam
Arrizabalaga, Leire
Cirella, Assunta
Teijeira, Álvaro
Medina-Echeverz, José
Melero, Ignacio
Berraondo, Pedro
Aranda, Fernando
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
title Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
title_full Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
title_fullStr Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
title_full_unstemmed Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
title_short Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
title_sort mouse models of peritoneal carcinomatosis to develop clinical applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956655/
https://www.ncbi.nlm.nih.gov/pubmed/33669017
http://dx.doi.org/10.3390/cancers13050963
work_keys_str_mv AT bellaangela mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT ditraniclaudiaaugusta mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT fernandezsendinmyriam mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT arrizabalagaleire mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT cirellaassunta mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT teijeiraalvaro mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT medinaecheverzjose mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT meleroignacio mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT berraondopedro mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications
AT arandafernando mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications